OZEM
Roundhill Investments - GLP-1 & Weight Loss ETF·Financial Services
32.38
1.278%(+0.41)
Market ClosedLast Updated: — ET
52W L: $22.6452W H: $37.15
Roundhill Investments - GLP-1 & Weight Loss ETF·Financial Services
Weight loss drugs are big business, with the GLP-1 receptor agonist market expected to nearly triple in size to $185 billion by 2033, a compound annual growth rate of about 12.4%. Although increasingly a global medical phenomenon, the bulk of the market still exists in the United States, and domestic investors can get in on the action by targeting companies that manufacture these powerful drugs.
For the past two years, GLP-1 medications have been a fixture of consumer trend analysis, discussed by everyone from CNBC to sell-side strategists to management consultants. Real apparel expenditure outperformed total consumer spending by approximately 400 basis points per month on average in 2025, a trend our analysis attributes in part to GLP-1-driven wardrobe replacement. The oral pill launch likely means the population of GLP-1 users will grow materially over the next several years.
Roundhill GLP-1 and Weight Loss ETF (NASDAQ: OZEM - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 44,401 shares, an increase of 47.1% from the January 15th total of 30,184 shares. Approximately 2.7% of the shares of
I recommend buying the Roundhill GLP-1 & Weight Loss ETF (OZEM) for strategic exposure to the weight loss drug sector. OZEM offers diversified access to leading GLP-1 innovators like Novo Nordisk and Eli Lilly, with a 34x earnings multiple versus Eli Lilly's 45x. AI-driven drug discovery, highlighted by the Nvidia-Eli Lilly partnership, is a major catalyst for sector growth and future upside.
President Donald Trump may be creating investment opportunities in themes and helping put an emphasize thematic ETFs.
After a lackluster first half of 2025, healthcare stocks staged a comeback, posting the best performance among the 11 S&P 500 sectors over the past six months.
